Scientists combine CAR t therapy and bone marrow transplant to attack tough blood cancers
NCT ID NCT07162038
First seen Jun 24, 2026 · Last updated Aug 05, 2026 · Updated 5 times
Summary
This early-phase trial tests whether giving anti-CD19 CAR T cells together with a half-matched bone marrow transplant can safely treat aggressive blood cancers like leukemia and lymphoma. About 155 adults aged 18 to 75 with CD19-positive cancers will receive the combined therapy after chemotherapy. The main goal is to check safety and see if the treatment helps prevent the cancer from coming back.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Anti-CD19 CAR T cells (genetically modified immune cells) and donor bone marrow stem cells
- What this could lead to
- If it works, this could offer a new treatment option for people with aggressive blood cancers that have few other choices.
- What could go wrong
- This is a very early phase 1 trial with only 155 people, so it is not yet known if the combination is safe or effective. There are serious risks like severe immune reactions and infections.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGIC MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- AI platform aims to unlock Real-World cancer data on a massive scale
- 10,000 DNA samples could reveal hidden genetic triggers for leukemia and lymphoma
- Could a common arthritis drug shield transplant patients from a dangerous virus?
- New biologic MK-1045 targets Hard-to-Treat blood cancers
- Blood cancer patients may need higher antibiotic doses to beat superbugs
- New antibody may offer safer shield against transplant complications